Sarepta stock price target cut to $62 from $137 by TD Cowen

Sarepta Therapeutics (SRPT) faces significant headwinds after a second patient death related to its Elevidys treatment, leading to a temporary suspension of shipments for non-ambulatory DMD patients and withdrawal of its FY25 revenue guidance of $2.3-2.6 billion. Consequently, multiple analysts have downgraded the stock, citing safety concerns and reducing price targets, with TD Cowen lowering its target to $62 from $137; the company is now proposing an enhanced immunosuppression regimen. The risk profile potentially affects all Duchenne muscular dystrophy patients, introducing uncertainties regarding Sarepta's future revenue and broader development pipeline, though UBS maintains a buy rating, noting the difficulty of withdrawing a drug from the market.

Analysis

Sarepta Therapeutics (SRPT) is confronting a significant crisis following the announcement of a second patient death from acute liver failure in a non-ambulatory individual receiving its Elevidys treatment for Duchenne muscular dystrophy (DMD). This event has precipitated a sharp 47% decline in SRPT's stock price over the past week, with shares trading near their 52-week low of $18.30. Consequently, Sarepta has temporarily suspended Elevidys shipments for non-ambulatory DMD patients and withdrawn its fiscal year 2025 revenue guidance of $2.3-2.6 billion. The company is now proposing an enhanced immunosuppression regimen, including sirolimus, to mitigate these safety risks and has paused dosing in its ENVISION trial. The financial community has reacted strongly, with TD Cowen lowering its price target on SRPT to $62.00 from $137.00 while maintaining a Buy rating. Other analysts have been more bearish: Morgan Stanley downgraded the stock to Equalweight, cutting its price target to $40.00; H.C. Wainwright downgraded to Sell with a $10.00 target; and BMO Capital and Piper Sandler issued downgrades with targets of $70.00 and $36.00, respectively. These actions stem from concerns that the risk profile of Elevidys could extend beyond non-ambulatory patients, creating substantial uncertainty for Sarepta's future revenue and overall development pipeline. Despite these headwinds, UBS maintained a Buy rating with an $85.00 price target, highlighting the complexities involved in withdrawing a marketed drug, but the prevailing analyst sentiment reflects apprehension about potential additional patient deaths and permanent impairment to Elevidys’ sales and terminal asset value.

Key Decisions for Investors

• Investors should exercise extreme caution given the severe safety issues surrounding Elevidys, the resultant suspension of shipments to a key patient group, and the complete withdrawal of FY25 revenue guidance, all of which indicate a significantly deteriorated outlook for Sarepta Therapeutics.
• The wave of analyst downgrades and substantial price target reductions, such as TD Cowen's cut to $62 from $137 and H.C. Wainwright's sell rating with a $10 target, signal profound concerns regarding Elevidys' commercial viability and Sarepta's intrinsic value.
• Closely monitor Sarepta's engagement with regulatory authorities regarding the proposed enhanced immunosuppression regimen with sirolimus, as the outcome will be critical in determining the future market access of Elevidys and the potential for any recovery in the stock's valuation.